Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma

This is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies. This phase I trial evaluates the effects of casdatifan on certain genes linked to kidney cancer growth and tests it for the treatment of clear cell renal cell cancer that has not responded to previous treatment (refractory) and that has spread from where it first started (primary site) to other places in the body (metastatic). Casdatifan may stop the growth of tumor cells by blocking some of th

Trial Details

NCT ID
NCT07748988
Phase
PHASE1
Sponsor
Vanderbilt-Ingram Cancer Center
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • casdatifan
Locations (sample)
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Signed and dated written informed consent.
  • Male or female ≥ 18 years of age on the day of signing informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Histologically confirmed metastatic clear cell renal cell carcinoma (ccRCC)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →